Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus PENTACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus PENTACEF.
CEFTRIAXONE IN PLASTIC CONTAINER vs PENTACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic